2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2368 Age-dependent transcriptional programming differentially regulates CAR-T cell phenotype, inflammatory function, and antitumor activity.

Duna Massillon, PhD, Emiliano Roselli2, Hiroshi Kotani3, Allan Pavy, PhD4, Amelia Harper5, Meredith L. Stone, PhD6, Marco Davila, MD, PhD7
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Background

Despite the remarkable success of CAR-T cell therapy in treating hematologic malignancies, this type of therapy remains constrained by cytokine release syndrome (CRS), a potentially life-threatening inflammatory toxicity and a major cause of treatment-related morbidity and mortality. Older patients are disproportionately affected, experiencing more severe CRS and poorer clinical outcomes than younger individuals, suggesting that aging fundamentally alters CAR-T cell function. We recently identified IFNγ-driven cytokine skewing as a determinant of toxicity in a murine CRS and neutropenia model.  Aging also profoundly alters T-cell differentiation and function however, the mechanisms linking donor age and CAR-T phenotype, efficacy, and inflammatory potential remain poorly understood. RNA-sequencing revealed that T-bet (encoded by TBX21), a master transcriptional regulator of T cell differentiation and function, is upregulated in CAR T cells derived from aged donors. Whether increased T-bet expression drives age-related changes in CAR-T cell efficacy and toxicity has not yet been determined.

Methods

CAR-T cells were generated from young (6-12 weeks) and aged (≥72 weeks) C57BL/6J mice using CD19-28ζ (28z) or CD19-4-1BBζ (BBz) CAR constructs. A subset of CAR-T cells was engineered to constitutively express T-bet (T-bet armed). Cytotoxicity was assessed using 72-hour real-time xCELLigence assays at effector-to-target ratios of 10:1 and 1:1. Phenotypic analyses were performed by flow cytometry, cytokines were quantified by multiplex analysis, and targeted transcriptional profiling was performed to characterize aged-dependent gene-expression differences. Statistical analyses were performed using unpaired two-tailed t-tests or two-way ANOVA with Tukey's multiple-comparison test, as appropriate. A two-sided P value <0.05 was considered statistically significant.

Results

Aged CAR-T products were enriched for CD8+ T and effector-memory cell populations, whereas young CAR-T cells retained a more balanced CD4+/CD8+ composition and greater central memory differentiation. Donor age profoundly influenced CAR-T cell function independent of CAR construct. At a 10:1 E:T ratio, aged CAR-T cells demonstrated faster tumor cell killing than young CAR-T cells, consistent with enhanced effector capacity. T-bet armed CAR-Ts exerted age- and construct-dependent effects. At high E:T ratios (10:1), T-bet-arming had a minimal effect on cytotoxicity regardless of age and construct. At 1:1 E:T ratios, T-bet arming had little effect on aged 28z and BBz CAR-T cells. In contrast, T-bet arming modestly reduced late cytotoxicity by young 28z CAR T cells and markedly decreased the anti-tumor activity in young BBz CAR-T cells resulting in progressive tumor cell outgrowth.

Enhanced cytotoxicity of aged CAR-T cells was accompanied by a distinct inflammatory secretory profile characterized by significantly increased RANTES (CCL5), MIP-1α (CCL3), and IL-6, while IFN-γ, TNF-α, and IL-2 production remained largely unchanged. Gene-expression profiling further demonstrated extensive age-dependent transcriptional remodeling involving pathways regulating proliferation, apoptosis, cytokine signaling, chemokine production, and T-cell differentiation. Notably, aged CAR-T cells exhibited increased expression of inflammatory mediators and effector-associated transcriptional programs, whereas young CAR-T cells preferentially expressed genes associated with stemness, memory formation, and proliferative potential.

Conclusions

Aging intrinsically reprograms CAR-T cells toward an inflammatory CD8-dominant effector state characterized by rapid tumor-cell killing, increased chemokine production, and broad transcriptional remodeling of immune activation pathways. While this phenotype enhances immediate cytotoxicity, it is accompanied by increased inflammatory mediators that may contribute to the greater incidence and severity of CRS observed in older patients. The effects of T-bet overexpression are strongly influenced by donor age and CAR costimulatory signaling identifying a previously unrecognized interaction between aging, T-bet-dependent programming, and CAR design. These findings identify aging as a fundamental determinant of CAR-T cell biology and suggest that age-specific engineering strategies may be required to optimize both efficacy and safety of adoptive CAR-T cell immunotherapy.

Meredith L. Stone, PhD: No relevant conflicts of interest to declare.